Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Protalix BioTherapeutics (PLX) Equity Ratio (2016 - 2025)

Historic Equity Ratio for Protalix BioTherapeutics (PLX) over the last 17 years, with Q3 2025 value amounting to 0.64.

  • Protalix BioTherapeutics' Equity Ratio rose 2206.48% to 0.64 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.64, marking a year-over-year increase of 2206.48%. This contributed to the annual value of 0.59 for FY2024, which is 4803.92% up from last year.
  • Per Protalix BioTherapeutics' latest filing, its Equity Ratio stood at 0.64 for Q3 2025, which was up 2206.48% from 0.64 recorded in Q2 2025.
  • In the past 5 years, Protalix BioTherapeutics' Equity Ratio ranged from a high of 0.64 in Q3 2025 and a low of 0.2 during Q3 2022
  • Moreover, its 5-year median value for Equity Ratio was 0.31 (2024), whereas its average is 0.23.
  • In the last 5 years, Protalix BioTherapeutics' Equity Ratio tumbled by 805769.84% in 2022 and then surged by 208958.2% in 2024.
  • Quarter analysis of 5 years shows Protalix BioTherapeutics' Equity Ratio stood at 0.08 in 2021, then tumbled by 132.77% to 0.19 in 2022, then surged by 308.46% to 0.4 in 2023, then surged by 48.04% to 0.59 in 2024, then rose by 9.27% to 0.64 in 2025.
  • Its Equity Ratio stands at 0.64 for Q3 2025, versus 0.64 for Q2 2025 and 0.61 for Q1 2025.